Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 9/20 | 0.48 |
| ▸ | RXRB | P28702 | 6/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.47 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | RARB | P10826 | 6/20 | 0.45 |
| ▸ | RARG | P13631 | 6/20 | 0.45 |
| ▸ | RARA | P10276 | 5/20 | 0.45 |
| ▸ | RXRG | P48443 | 4/20 | 0.44 |
| ▸ | HNF4A | P41235 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6144413 | 1.00 | RXRA (0.48) | RXRARXRBCYP26A1CYP26B1CYP3A4 | |
| SCHEMBL6143663 | 0.85 | RXRA (0.53) | RXRARXRBCYP26A1CYP26B1CYP3A4 | |
| SCHEMBL6143660 | 0.85 | RXRA (0.53) | RXRARXRBCYP26A1CYP26B1CYP3A4 | |
| SCHEMBL6143532 | 0.84 | CYP26A1 (0.55) | RXRARXRBCYP26A1CYP26B1CYP3A4 | |
| SCHEMBL6147150 | 0.83 | RXRA (0.51) | RXRARXRBCYP26A1CYP26B1CYP3A4 | |
| SCHEMBL6147157 | 0.83 | RXRA (0.51) | RXRARXRBCYP26A1CYP26B1CYP3A4 | |
| SCHEMBL6143928 | 0.82 | RXRA (0.50) | RXRARXRBCYP26A1CYP26B1CYP3A4 | |
| SCHEMBL6146933 | 0.82 | RXRA (0.50) | RXRARXRBCYP26A1CYP26B1CYP3A4 | |
| SCHEMBL6143925 | 0.82 | RXRA (0.50) | RXRARXRBCYP26A1CYP26B1CYP3A4 | |
| SCHEMBL6144394 | 0.81 | RXRA (0.49) | RXRARXRBCYP26A1CYP26B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280757-B1 | NEW GAMMA SELECTIVE RETINOIDS | HOFFMANN LA ROCHE (CH) | 2005-08-17 | — | — | EP | disclosed |
| US-6603012-B2 | RAR selective retinoid agonists | HOFFMANN-LA ROCHE INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020026060-A1 | RAR selective retinoid agonists | F.HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026060-A1 | RAR selective retinoid agonists | RARA, RARG, RARB | RXRA 4/4885RXRB 6/4885CYP26A1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.